Portfolio company Cardiosense received FDA De Novo classification for its novel cardiac technology for heart failure care.
Cardiosense leverages wearable sensing technology, advanced signal processing, and deep learning to transform physiological data into actionable clinical insight, focusing on heart failure management
Cardiosense leverages wearable sensing technology, advanced signal processing, and deep learning to transform physiological data into actionable clinical insight, focusing on heart failure management.